- Price
- $28.79
- Day
- +4.88%
- Mkt Cap
- $1.15B
- 52W Range
- $16.12 – $35.29
- Volume
- 380.6K
- Beta
- 0.00
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on August 31, 2026, the compensation committee of Apnimed's board of directors granted 10 new non-executive employees non-qualified stock options to purchase an aggregate of 428,428 shares of the Company's common stock under Apnimed's 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $26.85, which is equal to Apnimed's closing trading price on September 1, 2026. One-fourth of the shares underlying each of the employee's stock options will vest on the first anniversary of each employee's start date and in equal monthly installments thereafter for the next three years, subject to such employee's continued employment with the Company on such vesting dates.
Read full article
Apnimed's (NASDAQ: APMD - Get Free Report) quiet period is set to expire on Wednesday, September 9th. Apnimed had issued 12,000,000 shares in its public offering on July 31st. The total size of the offering was $192,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and any underwriters that worked
Read full article
Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea (OSA).
Read full article